Inhibition of peroxidase activity of cytochrome c: De novo compound discovery and validation

Molecular Pharmacology

Volumn 88, Issue 3, 2015, Pages 421-427

  Bakan, Ahmet ^a   Kapralov, Alexandr A ^b   Bayir, Hulya ^b   Hu, Feizhou ^a   Kagan, Valerian E ^b   Bahar, Ivet ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; ENZYME INHIBITOR; MOLECULAR LIBRARY; PEROXIDASE;

AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; MOLECULAR DOCKING; MOLECULAR GENETICS; MOLECULAR LIBRARY; PHARMACOLOGY;

AMINO ACID SEQUENCE; CATALYTIC DOMAIN; ELECTRON TRANSPORT COMPLEX IV; ENZYME INHIBITORS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PEROXIDASES; SMALL MOLECULE LIBRARIES;

EID: 84939812727     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.097816     Document Type: Article

References (22)

1. Atkinson J, Kapralov AA, Yanamala N, Tyurina YY, Amoscato AA, Pearce L, Peterson J, Huang Z, Jiang J, and Samhan-Arias AK et al. (2011) A mitochondria-targeted inhibitor of cytochrome c peroxidase mitigates radiation-induced death. Nat Commun 2:497.
2. Baell JB and Holloway GA (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719-2740.
3. Bakan A, Dutta A, Mao W, Liu Y, Chennubhotla C, Lezon TR, and Bahar I (2014) Evol and ProDy for bridging protein sequence evolution and structural dynamics. Bioinformatics 30:2681-2683.
4. Bakan A, Nevins N, Lakdawala AS, and Bahar I (2012) Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules. J Chem Theory Comput 8:2435-2447.
5. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, and Bourne PE (2000) The protein data bank. Nucleic Acids Res 28: 235-242.
6. Bushnell GW, Louie GV, and Brayer GD (1990) High-resolution three-dimensional structure of horse heart cytochrome c. J Mol Biol 214:585-595.
7. Hanske J, Toffey JR, Morenz AM, Bonilla AJ, Schiavoni KH, and Pletneva EV (2012) Conformational properties of cardiolipin-bound cytochrome c. Proc Natl Acad Sci USA 109:125-130.
8. Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, and Stahl MT (2010) Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model 50:572-584.
9. Humphrey W, Dalke A, and Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-38, 27-28.
10. Irwin JJ and Shoichet BK (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177-182.
11. Jiang J, Bakan A, Kapralov AA, Silva KI, Huang Z, Amoscato AA, Peterson J, Garapati VK, Saxena S, and Bayir H et al. (2014) Designing inhibitors of cytochrome c/cardiolipin peroxidase complexes: mitochondria-targeted imidazole-substituted fatty acids. Free Radic Biol Med 71:221-230.
12. Kagan VE, Bayir A, Bayir H, Stoyanovsky D, Borisenko GG, Tyurina YY, Wipf P, Atkinson J, Greenberger JS, and Chapkin RS et al. (2009a) Mitochondria-targeted disruptors and inhibitors of cytochrome c/cardiolipin peroxidase complexes: a new strategy in anti-apoptotic drug discovery. Mol Nutr Food Res 53:104-114.
13. Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA, Jiang J, Stoyanovsky DA, Wipf P, and Kochanek PM et al. (2009b) Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med 46: 1439-1453.
14. Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA, Osipov AN, Belikova NA, Kapralov AA, and Kini V et al. (2005) Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. Nat Chem Biol 1:223-232.
15. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, and Neveu V et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39:D1035-D1041.
16. MacKerell AD, Brooks B, Brooks C, Nilsson L, Roux B, Won Y, and Karplus M (2002) CHARMM: the energy function and Its parameterization. Encyclopedia of Computational Chemistry John Wiley & Sons, Chichester, UK.
17. Maity H, Maity M, Krishna MMG, Mayne L, and Englander SW (2005) Protein folding: the stepwise assembly of foldon units. Proc Natl Acad Sci USA 102: 4741-4746.
18. Nelson MT, Humphrey W, Gursoy A, Dalke A, Kale LV, Skeel RD, and Schulten K (1996) NAMD: a parallel, object-oriented molecular dynamics program. Int J High Perform Comput Appl 10:251-268.
19. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004) UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 25:1605-1612.
20. Rush TS, 3rd, Grant JA, Mosyak L, and Nicholls A (2005) A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48:1489-1495.
21. Sinibaldi F, Howes BD, Piro MC, Polticelli F, Bombelli C, Ferri T, Coletta M, Smulevich G, and Santucci R (2010) Extended cardiolipin anchorage to cytochrome c: a model for protein-mitochondrial membrane binding. J Biol Inorg Chem 15: 689-700.
22. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J, Darian E, Guvench O, Lopes P, and Vorobyov I et al. (2010) CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem 31:671-690.